Around 10.5 million Medicare beneficiaries were affected by chronic wounds in 2019.1

A chronic wound is generally defined as any wound that fails to heal within a reasonable timeframe. Chronic wounds can be categorized into the following four groups: arterial, pressure, diabetic, and venous. The recurrence rate for venous leg ulcers (VLUs) is estimated to be between 60-70%.2

Despite the well-established standard of care (SOC) for chronic wounds, which

Type 2 diabetes accounts for the majority of the more than 500 million cases of di-abetes worldwide.1

The increasing prevalence of type 2 diabetes is driven by modifiable risk factors including obesity, poor metabolic health, sedentary Lifestyles, tobacco use, and alcohol consumption.2

Background: Venous leg ulcers (VLU), a painful and debilitating condition, adversely affect patient quality of life and impose a burden on health care systems across the globe. Existing standard of care (SOC) yields limited healing success, emphasizing the need for new and more effective treatment strategies.

Methods: An interim analysis of this multicenter, prospective, randomized controlled modified platform clinical trial evaluated the efficacy of cellular, acellular, and matrix-like products (CAMPs) with SOC versus SOC alone. The primary endpoint was percentage of target ulcers achieving complete wound closure in 12 weeks, defined as 100% reepithelialization without drainage for two consecutive weeks, confirmed by blinded independent review.

Background: Diabetic foot ulcers (DFUs) are chronic wounds associated with high morbidity, mortality, and economic burden. Current standard of care (SOC) achieves less than optimal healing rates, highlighting the need for novel and costeffective therapies.

Methods: An interim analysis of this multicenter, prospective, randomized controlled modified platform clinical trial evaluated the efficacy of multiple cellular, acellular, and matrix-like prod-ucts (CAMPs) with SOC versus SOC alone. The primary endpoint was percentage of target ulcers achieving complete wound closure in 12 weeks, defined as 100% reepithelialization without drainage for two consecutive weeks, confirmed by blinded independent review.